What to do with a man with M0 or M1 disease who is progressing on treatment

Is the addition of enzalutamide (Xtandi) to an LHRH agonist now the appropriate standard of care for a man with M0 or M1 prostate cancer who starts to progress on treatment with an LHRH agonist alone? … READ MORE …

Publication of final data from the TRAPEZE trial

Some 2½ years ago, James presented data from the TRAPEZE trial at the annual meeting of the American Society of Clinical Oncology in Chicago. At the time, we described these data as “unsurprising.” … READ MORE …

Is prostate-specific radiation still of any value in men diagnosed with distant metastases?

In some cancers, debulking of the primary tumor, also called cytoreduction, either with radiation or surgery, has been found to slow progression. Is that true of prostate cancer? … READ MORE …

Maha Hussain’s keynote lecture from the GU Cancers Symposium

A detailed report on Dr. Maha Hussain’s keynote lecture at the Genitourinary Cancers Sysmposium in San Francisco — on the management of hormone-naive, progressive prostate cancer — is now available on the UroToday web site. This may well be of interest to many readers. You do have to register as a member of UroToday to read this.

An update on development of galeterone in the treatment of mCRPC

In a statement from Tokai Pharmaceuticals, the company has provided additional information about the clinical development of the investigational drug galeterone in treatment of metastatic, castration resistant prostate cancer (mCRPC). … READ MORE …

Unexpected and perhaps intriguing data from the STAMPEDE trial

In a poster presentation to be given at the upcoming Genitourinary Cancers Symposium in San Francisco later this week, data from the STAMPEDE trial in the UK appear to have demonstrated a result that few people seem to have expected. … READ MORE …

Clinical and therapeutic histories of men who actually die of mCRPC

Despite all the prostate cancer research over the past 30 or so years, we still have limited information about the clinical and therapeutic history of prostate cancer in men who have progressive disease and go on to die of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,368 other followers